DaVita Stock
DaVita Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Country
- United States
- CEO
- Javier J. Rodriguez
- Employees
- 78,000
- Market cap
- $12 B
- IPO
- 31/10/1995
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
DaVita stock: price history
1D
-1.0%
1W
+4.5%
1M
-3.4%
6M
+26.6%
YTD
+64.9%
1Y
+49.5%
2Y
+13.6%
5Y
+66.9%
10Y
+198.0%
Next earnings date
Next earnings date
28/10/2026 (in 11 days)
Volatility around earnings
~171% stronger price swings than usual
DaVita stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Ask the agents about DaVita
Analyst assessment of DaVita
PRICE TARGET LOW
US$215.00
CONSENSUS
US$235.67
MEDIAN
US$222.00
PRICE TARGET HIGH
US$270.00
0
STRONG BUY
10
BUY
12
HOLD
1
SELL
0
STRONG SELL
23
TOTAL · Hold
As of: 07/08/2026
DaVita stock metrics
P/E
16.11
P/B
-15.86
EV/EBITDA
7.99
RETURN ON EQUITY
-34.7%
NET MARGIN
7.5%
DEBT/EQUITY
-14.09
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
97.9%
FLOAT SHARES
62,476,086
AVG. DAILY VOLUME (30D)
643,868
Insider transactions (SEC)
Maughan David Paul
Schoppert Wendy Lee
Arway Pamela M
YALE PHYLLIS R
Hollar Jason M.
Institutional holders
Dividends & Stock splits
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about DaVita stock
What does DaVita do?
DaVita Inc. is a company in the Healthcare sector, Medical - Care Facilities industry, headquartered in United States.
The CEO is Javier J. Rodriguez, the company employs around 78,000 people.
The IPO was on 31/10/1995; the stock trades on NYSE under the ticker DVA.
What do analysts say about DaVita stock?
23 analysts rate the stock, the consensus is Hold (as of 07/08/2026).
The average price target is US$235.67, ranging from US$215.00 to US$270.00, with a median of US$222.00.
This is an external assessment, not a statement by Market Jury.
When does DaVita report next?
The next earnings date is 28/10/2026.
Around past earnings, price swings were roughly 171% stronger than usual.
Does DaVita pay a dividend?
No, DaVita currently does not pay a dividend.
Which stocks are comparable to DaVita?
Comparable stocks include HCA Healthcare, Tenet Healthcare, Universal Health Services, Hims & Hers Health, LifeStance Health Group, Concentra Group Holdings Parent, Acadia Healthcare Company and Aveanna Healthcare Holdings.
How can I get DaVita stock analyzed?
Clicking "Analyze stock" lets five strategies assess DaVita against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.